Amid ongoing efforts to increase regulatory transparency, FDA Commissioner Marty Makary announced plans to publicly release complete response letters (CRLs) for drug applications at the time they are issued. This initiative responds to public interest in understanding the rationale behind drug approvals and denials, aiming to boost agency credibility. The policy aligns with an executive order emphasizing openness in scientific data communication, marking a shift toward greater transparency in regulatory communications.